Quince Therapeutics schedules special meeting for Series C conversion and share issuance

Quince Therapeutics, Inc.

Quince Therapeutics will hold a special meeting to approve issuance of shares upon conversion of 211,301.868 Series C Preferred shares into 10,987,728 common shares.
Pro forma balance sheet as of June 30, 2026 reflects reclassification of $6.3 million Series C warrant liability to equity.
The share issuance may exceed 20% of outstanding common stock and could result in change of control under Nasdaq Listing Rule 5635(b).
Company filed unaudited pro forma condensed consolidated financial information with the SEC on August 17, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.